A prospective, multicenter, randomized, controlled trial of non-healing diabetic foot ulcers treated with standard care with or without br-ac: top-line results
DOI:
https://doi.org/10.63676/qpavmd61Keywords:
Diabetic Foot, Foot Ulcer, Amniotic Membrane, Randomized Controlled TrialAbstract
Aims: The primary objective of this randomized controlled trial was to determine whether non-ischemic, non-infected Wagner Grade 1-2 diabetic foot ulcers (DFUs) treated with standard care plus BioRetain Amniochorion (BR-AC) resulted in a higher probability of complete wound closure compared to standard care alone.
Methods: Following a two-week run-in and stratified randomization, subjects attended clinic weekly for 12 weeks or until complete healing was observed. At each visit the wound was measured, debrided as needed, evaluated for infection and treated with or without BR-AC, followed by application of a non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, and a secondary retention bandage, including a standardized off-loading device. Bayesian statistics were used to evaluate the likelihood of healing.
Results: The Intent to Treat (ITT) analysis showed a posterior mean absolute difference in healing rates between treatment and control of 0.22 (95% CrI: –0.01 to 0.45), with a 96.8% posterior probability that the effect exceeds zero and a posterior mean risk ratio of 1.9 (95% CrI: 0.87–3.2). The posterior mean probability of closure was 0.31 (95% CrI: 0.15–0.47) for the standard of care (SOC) arm (3% higher than the prior probability) compared with 0.53 (95% CrI: 0.34–0.74) for the treatment arm (18% higher than the prior probability). The treatment distribution was centered substantially higher, with limited overlap between intervals. The SOC arm showed a 36.4% posterior probability of closing by more than 50% at 12 weeks, compared with a 56.4% posterior probability for the treatment arm.
Conclusion: This is the first controlled DFU trial examining a birth tissue product prepared using the ‘Bioretain’ method designed to retain integrity and contents. With only a 3.2% probability that BR-AC is not superior to SOC, these results provide strong evidence of treatment benefit.
References
1. Huang W, Chen Y, Wang N et al. Effectiveness and safety of human amnion/chorion membrane therapy for diabetic foot ulcers: An updated meta-analysis of randomized clinical trials. Wound Repair Regen. 2020; 28(6): 739-750. https://doi.org/10.1111/wrr.12851
2. Lavery LA, Fulmer J, Shebetka KA et al. The efficacy and safety of Grafix(®) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014; 11(5): 554-560. https://doi.org/10.1111/iwj.12329
3. Tettelbach W, Cazzell S, Reyzelman AM et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J. 2019; 16(1): 19-29. https://doi.org/10.1111/iwj.12976
4. Protzman NM, Mao Y, Long D et al. Placental-derived biomaterials and their application to wound healing: a review. Bioengineering. 2023; 10(7). https://doi.org/10.3390/bioengineering10070829
5. Davis JS. Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Bull. Johns Hopkins Hosp. 1910; 15: 307-396
6. Gruss, J. S., Jirsch, D. W. Human amniotic membrane: a versatile wound dressing. Can Med Assoc J. 1978; 118(10): 1237-1246
7. Niknejad H, Peirovi H, Jorjani M et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008; 15: 88-99. https://doi.org/10.22203/ecm.v015a07
8. Islam R, Rahman S, Asaduzzaman SM et al. Properties and therapeutic potential of human amniotic membrane. Asian J Dermatol. 2015; 7: 1-12. https://doi.org/10.3923/ajd.2015.1.12
9. Serena TE, Carter MJ. Le LT et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen. 2014; 22(6): 688-693 https://doi.org/10.1111/wrr.12227
10. DiDomenico LA, Orgill DP, Galiano RD et al. Aseptically processed placental membrane improves healing of diabetic foot ulcerations: prospective, randomized clinical trial. Plast Reconstr Surg Glob Open. 2016; 4(10): e1095. https://doi.org/10.1097/gox.0000000000001095
11. Rubio JA, Jiménez S, Lázaro-Martínez JL. Mortality in patients with diabetic foot ulcers: causes, risk factors, and their association with evolution and severity of ulcer. J Clin Med. 2020; 9(9). https://doi.org/0.3390/jcm9093009
12. Harrell FE, Jr Shih YC. Using full probability models to compute probabilities of actual interest to decision makers. Int J Technol Assess Health Care. 2001; 17(1): 17-26. https://doi.org/10.1017/s0266462301104034
13. Wasserstein RL, Schirm AL, Lazar NA. Moving to a World Beyond “p < 0.05”. The American Statistician. 2019; 73: 1-19. https://doi.org/10.1080/00031305.2019.1583913
14. Gelman A, Stern H. The difference between ‘significant’ and ‘not significant’ is not itself statistically significant. The American Statistician. 2006; 60: 328-331. https://doi.org/10.1198/000313006X152649
15. Good IJ. Good Thinking: The Foundations of Probability and Its Applications. 1983. University of Minnesota Press USA
Downloads
Published
Data Availability Statement
We are reporting on the main portion of the study, while awaiting the results of a crossover portion. The study is open label. Data will be made available through ClinicalTrials.Gov
Issue
Section
License
Copyright (c) 2025 International Journal of Tissue Repair
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
